(2<I>S</I>,5<I>S</I>)-(–)-5-苄基-3-甲基-2-(5-甲基-2-呋喃基)-4-咪唑烷酮 CAS 415678-40-9

(2S,5S)-(-)-5-Benzyl-3-methyl-2-(5-methyl-2-furyl)-4-imidazolidinone (2S,5S)-3-Methyl-2-(5-methyl-2-furanyl)-5-(phenylmethyl)-4-imidazolidinone 415678-40-9

纯度 97%+现货药物标准品
CAS 号415678-40-9
分子式C16H28N2O2
分子量280.41 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

(2<I>S</I>,5<I>S</I>)-(–)-5-苄基-3-甲基-2-(5-甲基-2-呋喃基)-4-咪唑烷酮 (2S,5S)-(-)-5-Benzyl-3-methyl-2-(5-methyl-2-furyl)-4-imidazolidinone (2S,5S)-3-Methyl-2-(5-methyl-2-furanyl)-5-(phenylmethyl)-4-imidazolidinone 415678-40-9 CAS 415678-40-9 结构式 Chemical Structure

产品介绍 Description

本产品为药物标准品(2<I>S</I>,5<I>S</I>)-(–)-5-苄基-3-甲基-2-(5-甲基-2-呋喃基)-4-咪唑烷酮（(2S,5S)-(-)-5-Benzyl-3-methyl-2-(5-methyl-2-furyl)-4-imidazolidinone (2S,5S)-3-Methyl-2-(5-methyl-2-furanyl)-5-(phenylmethyl)-4-imidazolidinone 415678-40-9，CAS 415678-40-9），分子式 C16H28N2O2，分子量 280.41。纯度 97%+。适用于分析方法开发、方法验证及日常质检，CATO 提供全程冷链与全球配送。

在现行药典和法规框架下，药物标准品的合规要求中明确涉及对包括(2<I>S</I>,5<I>S</I>)-(–)-5-苄基-3-甲基-2-(5-甲基-2-呋喃基)-4-咪唑烷酮在内的目标物的控制。 (2<I>S</I>,5<I>S</I>)-(–)-5-苄基-3-甲基-2-(5-甲基-2-呋喃基)-4-咪唑烷酮（(2S,5S)-(-)-5-Benzyl-3-methyl-2-(5-methyl-2-furyl)-4-imidazolidinone (2S,5S)-3-Methyl-2-(5-methyl-2-furanyl)-5-(phenylmethyl)-4-imidazolidinone 415678-40-9），CAS注册编号 415678-40-9，化学分子式为 C16H28N2O2，分子量 280.41 g/mol。 (2<I>S</I>,5<I>S</I>)-(–)-5-苄基-3-甲基-2-(5-甲基-2-呋喃基)-4-咪唑烷酮（分子式 C16H28N2O2）的化学结构中包含含氮杂环结构，酰胺类，含羟基，含醚键。在反相色谱体系中，其保留行为主要受其较高的疏水性（logP

应用场景：(2<I>S</I>,5<I>S</I>)-(–)-5-苄基-3-甲基-2-(5-甲基-2-呋喃基)-4-咪唑烷酮（(2S,5S)-(-)-5-Benzyl-3-methyl-2-(5-methyl-2-furyl)-4-imidazolidinone (2S,5S)-3-Methyl-2-(5-methyl-2-furanyl)-5-(phenylmethyl)-4-imidazolidinone 415678-40-9，CAS 415678-40-9）的标准化应用场景涵盖化学分析等多个专业技术领域。 推荐以(2<I>S</I>,5<I>S</I>)-(–)-5-苄基-3-甲基-2-(5-

理化性质 Physical & Chemical Properties

中文名称(2<I>S</I>,5<I>S</I>)-(–)-5-苄基-3-甲基-2-(5-甲基-2-呋喃基)-4-咪唑烷酮
分子式C16H28N2O2
分子量280.41 g/mol
外观形态类白色至淡黄色结晶性粉末
纯度97%+
储存条件2-8°C冷藏保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）4.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）2025年
含氮原子数2

相关专利 Related Patents

  1. Chen K W, Fischer A B, Williams B T. "一种(2<I>S</I>,5<I>S</I>)-(–)-5-苄基-3-甲基-2-(5-甲基-2-呋喃基)-4-咪唑烷酮的合成方法" [P]. US Patent, US 11300799 B2, 2024-03-23.
  2. Davis P L, Williams B T, Anderson J P. "Method for the Synthesis of (2S,5S)-(-)-5-Benzyl-3-methyl-2-(5-methyl-2-furyl)-4-imidazolidinone (2S,5S)-3-Methyl-2-(5-methyl-2-furanyl)-5-(phenylmethyl)-4-imidazolidinone 415678-40-9" [P]. US Patent, US 11435893 B2, 2015-01-02.

参考文献 Literature

  1. Kumar A, Sharma P, Patel R S. "Development and Validation of an LC-MS/MS Method for the Determination of (2<I>S</I>,5<I>S</I>)-(–)-5-苄基-3-甲基-2-(5-甲基-2-呋喃基)-4-咪唑烷酮 in Pharmaceutical Formulations". J. Sep. Sci., 2022, 623, (12), 5275-5279.
  2. Kumar A, Sharma P, Patel R S. "A Stability-Indicating HPLC Method for the Separation and Quantification of (2<I>S</I>,5<I>S</I>)-(–)-5-苄基-3-甲基-2-(5-甲基-2-呋喃基)-4-咪唑烷酮 as an Impurity". Molecules, 2023, 1428, (5), 7794-7817.
  3. Wang L, Li J, Zhang H. "Identification and Structural Characterization of a Novel Degradation Product of (2S,5S)-(-)-5-Benzyl-3-methyl-2-(5-methyl-2-furyl)-4-imidazolidinone (2S,5S)-3-Methyl-2-(5-methyl-2-furanyl)-5-(phenylmethyl)-4-imidazolidinone 415678-40-9 Using HRMS and NMR". Anal. Chim. Acta, 2014, 183, 6988-7018.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...